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Vasospastic Angina*
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Six decades ago Prinzmetal et al. (1) described a particular
form of angina that occurred at rest, in the absence of any
increase of myocardial oxygen demand, and was associated
with ST-segment elevation on electrocardiography rather
than with the usual ST-segment depression observed during
effort angina. The investigators suggested that this “variant
form of angina” was caused by a primary reduction of
coronary blood flow consequent to an increased “tonus” of
stenotic coronary arteries (1). Some years later, coronary
angiographic studies showed that variant angina was indeed
caused by coronary artery spasm (CAS) (2). Accordingly, it
is now often referred as vasospastic angina (VSA).
See page 1231
CAS is defined as a sudden, intense, reversible vasocon-
striction of a coronary artery branch resulting in subtotal or
total occlusion. It can occur in stenotic or angiographically
normal coronary segments, can be focal or diffuse, and can
involve 1 or multiple epicardial coronary arteries.
VSA occurs frequently at night or in the early morning,
but in some patients it prevails in the afternoon. Angina
episodes may be sporadic or present in clusters and may
spontaneously subside and then recur after a variable period
of time. Triggers of CAS also differ among patients, with
exercise, for example, inducing CAS in about 25% of
patients with VSA. Importantly, CAS can cause life-
threatening arrhythmias and sudden death, and prolonged
CAS is a cause of acute myocardial infarction (3). Accord-
ingly, a prompt diagnosis is mandatory to prevent these
serious complications; yet, the diagnosis of VSA is often
missed for months after symptom onset (4).
Of note, progress in this area has been limited, for 2 main
reasons. First, the prevalence of VSA is low (1% to 1.5% of
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making the enrollment of large numbers of patients difficult.
Second, calcium-channel blockers (CCBs) prevent CAS in
the majority of patients, thus limiting the need for new
forms of treatment. Yet, 10% to 20% of patients with VSA
are refractory or develop poorly tolerated side effects to
CCBs. Thus, elucidating the mechanisms of CAS might be
important, as it might lead to development of new forms of
treatment.
Pathogenesis of CAS
The pathogenetic substrate of CAS is constituted by a
nonspecific hyper-reactivity to vasoconstrictor agents of
smooth muscle cells (SMCs) in spastic coronary artery
segments (5). Local SMC hyper-reactivity is suggested by
the evidence that vasoconstrictor stimuli trigger CAS in
patients with VSA but not in patients with other forms of
angina and that, in patients with VSA, they trigger CAS in
the spastic but not in the remaining coronary segments. Of
note, CAS can be elicited in the same patient by several
constrictor stimuli that act through different receptors.
Accordingly, a specific receptor blocker is usually unable to
prevent CAS, likely because it contrasts a single trigger,
leaving the others unopposed. These observations suggest
an intracellular, post-receptor localization of the alteration
responsible for SMC hyper-reactivity (3).
In a porcine model of CAS, Shimokawa et al. (6) showed,
for the first time, that a possible major intracellular deter-
minant of SMC hyper-reactivity is increased activity of
Rho-kinase, an enzyme that favors SMC fiber contraction
through sensitization of myosin light chains to Ca2. In this
model, SMC Rho-kinase was indeed overexpressed, and a
Rho-kinase inhibitor, hydroxyfasudil, prevented CAS in-
duced by several vasoconstrictors (7).
The possible role of Rho-kinase in VSA was subsequently
confirmed by the observation that pre-treatment with fa-
sudil, a Rho-kinase inhibitor, prevented acetylcholine-
induced CAS in these patients (8).
Rho-Kinase Activity in
Peripheral Neutrophils and CAS
In this issue of the Journal, Kikuchi et al. (9) report exciting
new data on the possible involvement of Rho-kinase in
patients with VSA. They enrolled 53 consecutive patients
with chest pain who showed nonsignificant (50%) coro-
nary stenoses on angiography. Patients underwent intra-
coronary acetylcholine testing and were then allocated to 2
groups: patients who developed CAS (VSA group, n  33)
and patients who did not develop CAS (non-VSA group,
n  20). Rho-kinase activity was measured in circulating
eutrophils as the ratio of phosphorylated to total myosin-
inding subunit of myosin phosphatase.
Neutrophil Rho-kinase activity was significantly higher in
he VSA group than in the non-VSA group. In 21 patients
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was correlated with a significant reduction in symptoms.
The novel data provided by Kikuchi et al. (9) have
important pathogenetic and clinical implications and, at the
same time, raise some new stimulating questions in the still
foggy area of CAS.
Pathogenetic Implications
The demonstration that neutrophil Rho-kinase activity is
increased in VSA patients (9) lends further support to the
notion that enhanced Rho-kinase activity in SMCs may
contribute to the pathogenesis of CAS.
Importantly, evidence from this and other studies that
neutrophil Rho-kinase activity is also increased in other
cardiovascular diseases, such as systemic and pulmonary
hypertension, acute stroke, and stable angina, may have
far-reaching consequences. This increase might well reflect
the enhanced vasoconstriction that, in these diseases, is
detectable in the systemic, pulmonary, cerebral, and epicar-
dial coronary circulation, respectively. Accordingly, mea-
surement of neutrophil Rho-kinase activity might open the
way to new studies aimed at investigating the contributory
role of SMC dysfunction in cardiovascular diseases. Indeed,
although there are a great deal of data on the importance of
endothelial dysfunction, very little is known about the role
of SMC dysfunction.
With regard to VSA, however, the demonstration of
systemic enhancement of Rho-kinase activity fails to explain
the observation that CAS is usually localized to a specific
coronary segment or branch, suggesting the presence of yet
unknown local factors that cause local SMC hyper-reactivity
by further enhancement of SMC Rho-kinase activity and/or
by involvement of other constrictor pathways.
Clinical Implications
Kikuchi et al. (9) show that in patients with chest pain, a
simple, noninvasive measurement such as neutrophil Rho-
kinase activity might help identify those with VSA.
The investigators report, however, that neutrophil Rho-
kinase activity was similarly increased in patients with
chronic stable angina. Thus, although enhanced Rho-kinase
activity seems able to identify patients in whom chest pain
is caused by anatomic or functional alterations of epicardial
coronary arteries, a careful assessment of clinical features
remains crucial to discriminate patients with VSA from
those with stable angina.
The positive predictive power for VSA of neutrophil
Rho-kinase activity in the study by Kikuchi et al. (9) was
93%, using the cutoff value of phosphorylated myosin-
binding subunit/total myosin-binding subunit ratio of 1.18,
suggesting that this new biomarker might be particularly
helpful in patients in whom VSA is suspected but 24-h
ambulatory electrocardiographic monitoring fails to dem-
onstrate transient episodes of ST-segment elevation. In
these patients, the only way, at present, to demonstrateCAS is noninvasive ergonovine testing or invasive ergon-
ovine or acetylcholine testing. If the data of Kikuchi et al.
(9) are confirmed in future studies, assessment of neu-
trophil Rho-kinase activity might reduce the need for
provocative tests, which can be performed only by expe-
rienced teams.
It should be observed, however, that the negative
predictive power of the test was only 75%; thus, Rho-
kinase activity below the best cutoff value identified in the
study would not allow confident exclusion of a diagnosis
of VSA.
Importantly, Kikuchi et al. (9) also found that a
reduction of neutrophil Rho-kinase activity during CCB
treatment paralleled symptomatic improvement. This
finding suggests that this new biomarker might be useful
to monitor disease activity. It also suggests that Rho-
kinase might represent a valid therapeutic target for CAS
prevention and that CCBs may in part act by reducing
Rho-kinase activity (10). It remains to be established,
however, whether Rho-kinase activity measurement im-
proves the approach currently used to monitor VSA
activity, based on symptom assessment and on ambula-
tory electrocardiographic monitoring (4).
A last interesting aspect of the study by Kikuchi et al. (9)
concerns the group of non-VSA patients. Indeed, neutro-
phil Rho-kinase activity in these patients was significantly
higher compared with that of a reference group of healthy
controls (0.95  0.22 vs. 0.58  0.22, respectively, p 
.001 by t test). This observation might suggest that at least
ome patients without VSA had microvascular angina, in
hich SMC hyper-reactivity is confined to coronary micro-
irculation. This working hypothesis deserves assessment in
uture studies.
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